

Neratinib ExteNET

PRELIMINARY SCORE

CURATIVE

NEB

NON-CURATIVE

ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Neratinib ExteNET

FINAL SCORE

CURATIVE

NEB

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Therapeutic Indication: Extended adjuvant treatment of patients with early-stage hormone receptor-positive HER2-positive breast cancer who completed adjuvant trastuzumab-based therapy
Experimental Arm: Neratinib
Control Arm: Placebo

